Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1998-06-26
1999-12-21
Fay, Zohreh
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
514458, A61K 3133, A61K 31355
Patent
active
060049499
DESCRIPTION:
BRIEF SUMMARY
TECHNICAL FIELD
The present invention relates to an aqueous pharmaceutical composition which comprises sodium cromoglicate, an antiallergic agent, as an active ingredient and is useful as an eye drop, an injections and the like.
BACKGROUND ART
Aqueous pharmaceutical compositions in the form of eye drops, nasal drops or other, which comprise sodium cromoglicate [disodium salt of 1,3-bis(2-carboxychromon-5-yloxy)-2-hydroxypropane] having antiallergic activity as an active ingredient, have been used for preventive and therapeutic treatment of allergic conjunctivitis and allergic rhinitis.
It has been known that turbidity or precipitation tends to quite frequently appear in an aqueous pharmaceutical compositions comprising sodium cromoglicate as an active ingredient (see, for example, Japanese Patent Publication (KOKOKU) Nos. (Hei)4-66452/1992 and (Hei)4-78613/1992). It is recognized that the turbidity or precipitation is formed because a quaternary ammonium compound such as benzalkonium chloride, which is added as a preservative, reacts with sodium cromoglicate in the presence of trace metal ions (Pb.sup.2+, Ca.sup.2+, Cu.sup.2+, Al.sup.2+, Fe.sup.2+, Fe.sup.3+, Zn.sup.2+, Mg.sup.2+ or other) contained in the aqueous solution. Recent researches by the inventors of the present invention revealed that the reaction of benzalkonium chloride and sodium cromoglicate as well as resulting precipitation of reaction products are remarkably accelerated especially when concentrations of calcium ion and magnesium ion in the aqueous solution exceed 1 ppm and 10 ppm, respectively.
The generation of turbidity or precipitation seriously disturbs a process of manufacturing an aqueous pharmaceutical composition comprising sodium cromoglicate as an active ingredient, and this is also a significant problem from a viewpoint of storage stability of pharmaceutical preparations. However, considerable amounts of magnesium and calcium are contained as unavoidable impurities in bulk powder of sodium cromoglicate used as a raw material of pharmaceutical preparations, and distilled water for injection used as a solvent also contains a trace amount of metal ions. Therefore, it is practically impossible to achieve complete prevention of the generation of turbidity or precipitation by improving quality of raw materials and circumstantial conditions of a manufacturing process.
For the manufacture of an aqueous composition comprising sodium cromoglicate, methods of adding a precipitation inhibitor (sequestering agent) such as a chelating agent or a nonionic surfactant to the aqueous composition have thus been proposed as means to effectively prevent the generation of turbidity and precipitation.
For example, the following means have been proposed: an aqueous composition comprising sodium cromoglicate as an active ingredient that is added with an effective amount of a pharmaceutically acceptable chelating agent or sequestering agent when a concentration of a metal ion in the aqueous solution exceeds 0.40 ppm (Japanese Patent Publication (KOKOKU) No. (Sho)54-25082/1979); a water-soluble pharmaceutical preparation added with benzalkonium chloride as a preservative and polyoxyethylene sorbitan monooleate or polyoxyethylene hardened castor oil as an agent for preventing turbidity or precipitation (Japanese Patent Publication (KOKOKU) No. (Hei)4-66452/1992); and an external pharmaceutical preparation containing benzalkonium chloride as a preservative and a nonionic surfactant such as polyoxyethylene hardened castor oil in respective particular amounts (Japanese Patent Publication (KOKOKU) No. (Hei)4-78613/1992).
DISCLOSURE OF THE INVENTION
An object of the present invention is to provide an aqueous pharmaceutical composition comprising sodium cromoglicate as an active ingredient and useful as an eye drop or an injection, which is stable and free from generation of turbidity or precipitation during manufacturing processes, storage and distribution.
The inventors of the present invention conducted various studies to achieve the foregoing object
Ono Kazuhiro
Osada Takashi
Shima Junko
Suzuki Yukio
Fay Zohreh
Showa Yakuhin Kako Co. Ltd.
LandOfFree
Aqueous composition containing cromoglycic acid does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Aqueous composition containing cromoglycic acid, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Aqueous composition containing cromoglycic acid will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-505268